托珠单抗对比常规治疗在成人COVID-19中度或重度肺炎住院患者中的效果:一项随机临床试验
这项在法国9所大学医院开展的多中心、开放标签、贝叶斯随机临床试验,纳入131例需至少3 L/min氧气但未接受通气或入住ICU的COVID-19中度或重度肺炎患者,随机接受托珠单抗8 mg/kg静脉注射(第1天,必要时第3天)加常规治疗或单纯常规治疗。主要终点之一第4天WHO-CPS评分>5的比例在托珠单抗组为12例 vs 常规治疗组19例,后验绝对风险差-9.0%(90% CrI -21.0至3.1),未达到预设95%疗效阈值;另一主要终点第14天需要无创通气、机械通气或死亡的比例,托珠单抗组24% vs 常规治疗组36%,后验HR 0.58(90% CrI 0.33-1.00),达到预设疗效阈值。第28天死亡率两组无显著差异(调整HR 0.92,95% CI 0.33-2.53),严重不良事件托珠单抗组20例(32%) vs 常规治疗组29例(43%)(P=0.21)。作者结论认为托珠单抗未降低第4天WHO-CPS评分,但可能降低第14天无创通气、机械通气或死亡风险,需进一步研究确认这些初步结果。
要点
- 纳入标准:COVID-19中度或重度肺炎,需至少3 L/min氧气,但未接受通气且未入住ICU。
- 托珠单抗用法:8 mg/kg静脉注射,第1天给药,第3天如临床需要可重复。
- 第4天WHO-CPS评分>5:托珠单抗组12例 vs 常规治疗组19例,后验绝对风险差-9.0%(90% CrI -21.0至3.1),未达预设95%疗效阈值。
- 第14天无创通气、机械通气或死亡:托珠单抗组24% vs 常规治疗组36%,后验HR 0.58(90% CrI 0.33-1.00),达到预设疗效阈值。
- 第28天死亡:托珠单抗组7例 vs 常规治疗组8例,调整HR 0.92(95% CI 0.33-2.53),无显著差异。
适用人群与场景
- COVID-19中度或重度肺炎住院成人,需至少3 L/min氧气但未接受通气且未入住ICU。
- 来自法国9所大学医院,2020年3月31日至2020年4月18日纳入,随访28天。
诊断标准与关键阈值
- 主要终点之一:第4天世界卫生组织10点临床进展量表(WHO-CPS)评分>5。
- 主要终点之二:第14天生存且无需无创通气或机械通气。
处置流程与药物剂量
- 托珠单抗组:托珠单抗8 mg/kg静脉注射,第1天给药,第3天如临床需要可重复,加常规治疗。
- 常规治疗组:仅常规治疗,包括抗生素、抗病毒药、糖皮质激素、血管升压药支持和抗凝药。
研究设计与关键结果
- 多中心、开放标签、贝叶斯随机临床试验,131例随机(托珠单抗组64例,常规治疗组67例),托珠单抗组1例撤回知情同意未纳入分析,共130例分析;女性42例(32%),中位年龄64岁(IQR 57.1-74.3)。
- 第4天WHO-CPS评分>5:托珠单抗组12例 vs 常规治疗组19例,后验绝对风险差-9.0%(90% CrI -21.0至3.1),后验概率89.0%未达预设95%疗效阈值。
- 第14天需无创通气、机械通气或死亡:托珠单抗组24% vs 常规治疗组36%,后验HR 0.58(90% CrI 0.33-1.00),后验概率HR<1为95.0%,达到预设疗效阈值。
- 第14天机械通气或死亡:HR 0.58(90% CrI 0.30-1.09)。
- 第28天死亡:托珠单抗组7例 vs 常规治疗组8例,调整HR 0.92(95% CI 0.33-2.53)。
- 严重不良事件:托珠单抗组20例(32%) vs 常规治疗组29例(43%)(P=0.21)。
证据类型、等级与局限
- 证据类型:多中心、开放标签、贝叶斯随机临床试验(RCT)。
- 局限:作者结论指出需进一步研究以确认这些初步结果。
对床旁实践的改变
- 在需氧但未入ICU的COVID-19肺炎患者中,托珠单抗未降低第4天WHO-CPS评分,但可能降低第14天无创通气、机械通气或死亡风险;作者认为需进一步研究确认这些初步结果。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus disease 2019 (COVID-19).
OBJECTIVE: To determine whether tocilizumab (TCZ) improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia.
DESIGN, SETTING, AND PARTICPANTS: This cohort-embedded, investigator-initiated, multicenter, open-label, bayesian randomized clinical trial investigating patients with COVID-19 and moderate or severe pneumonia requiring at least 3 L/min of oxygen but without ventilation or admission to the intensive care unit was conducted between March 31, 2020, to April 18, 2020, with follow-up through 28 days. Patients were recruited from 9 university hospitals in France. Analyses were performed on an intention-to-treat basis with no correction for multiplicity for secondary outcomes.
INTERVENTIONS: Patients were randomly assigned to receive TCZ, 8 mg/kg, intravenously plus usual care on day 1 and on day 3 if clinically indicated (TCZ group) or to receive usual care alone (UC group). Usual care included antibiotic agents, antiviral agents, corticosteroids, vasopressor support, and anticoagulants.
MAIN OUTCOMES AND MEASURES: Primary outcomes were scores higher than 5 on the World Health Organization 10-point Clinical Progression Scale (WHO-CPS) on day 4 and survival without need of ventilation (including noninvasive ventilation) at day 14. Secondary outcomes were clinical status assessed with the WHO-CPS scores at day 7 and day 14, overall survival, time to discharge, time to oxygen supply independency, biological factors such as C-reactive protein level, and adverse events.
RESULTS: Of 131 patients, 64 patients were randomly assigned to the TCZ group and 67 to UC group; 1 patient in the TCZ group withdrew consent and was not included in the analysis. Of the 130 patients, 42 were women (32%), and median (interquartile range) age was 64 (57.1-74.3) years. In the TCZ group, 12 patients had a WHO-CPS score greater than 5 at day 4 vs 19 in the UC group (median posterior absolute risk difference [ARD] -9.0%; 90% credible interval [CrI], -21.0 to 3.1), with a posterior probability of negative ARD of 89.0% not achieving the 95% predefined efficacy threshold. At day 14, 12% (95% CI -28% to 4%) fewer patients needed noninvasive ventilation (NIV) or mechanical ventilation (MV) or died in the TCZ group than in the UC group (24% vs 36%, median posterior hazard ratio [HR] 0.58; 90% CrI, 0.33-1.00), with a posterior probability of HR less than 1 of 95.0%, achieving the predefined efficacy threshold. The HR for MV or death was 0.58 (90% CrI, 0.30 to 1.09). At day 28, 7 patients had died in the TCZ group and 8 in the UC group (adjusted HR, 0.92; 95% CI 0.33-2.53). Serious adverse events occurred in 20 (32%) patients in the TCZ group and 29 (43%) in the UC group (P = .21).
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of patients with COVID-19 and pneumonia requiring oxygen support but not admitted to the intensive care unit, TCZ did not reduce WHO-CPS scores lower than 5 at day 4 but might have reduced the risk of NIV, MV, or death by day 14. No difference on day 28 mortality was found. Further studies are necessary for confirming these preliminary results.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04331808.
参考来源
- Hermine O, Mariette X, Tharaux PL, et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021. PMID: 33080017. doi:10.1001/jamainternmed.2020.6820
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。